Literature DB >> 17631431

Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.

I E Katsoulis1, W L Wong, A K Mattheou, N Damani, J Chambers, J I Livingstone.   

Abstract

BACKGROUND: The pre-operative staging in oesophageal cancer is often challenging and underestimation of the extent of the disease may lead to unnecessary surgery. AIM: To audit the use and assess the value of fluorine-18 fluorodeoxyglucose positron emission tomography ((18)F FDG-PET) as a staging tool for thoracic oesophageal and gastro-oesophageal junction (GOJ) cancers in our oncological surgical practice. PATIENTS AND METHODS: Over a 3 year period, between 2002 and 2004, 134 patients with thoracic oesophageal or GOJ cancer were referred to our unit for treatment. The standard preoperative staging investigation in all cases was CT (thorax, abdomen and pelvis). A preoperative FDG-PET scan was further requested in 22 patients. The case notes of all the patients that underwent a FDG-PET scan were reviewed and compared with the preoperative imaging, the operative findings and the histopathology of the resected tumours.
RESULTS: Eighteen men and 4 women with a median age of 65 (range 43-79) years were studied. After FDG-PET, 13 out of 22 patients (59%) were deemed suitable for tumour resection. Twelve of the 13 patients were fit to undergo surgery. At laparotomy, 2 of those (17%) were found inoperable due to widespread disease. The sensitivity of CT versus FDG-PET to detect infiltrated lymph nodes was 29% (95% CI: 3-70) versus 71% (95% CI: 29-96) (P=0.0412), whereas both tests had 67% specificity (95% CI: 9-99) in detecting lymph nodes. The sensitivity and the specificity of CT versus FDG-PET to detect distant organ metastases (M1b) were 33% (95% CI: 4-77) and 88% (95% CI: 47-99) versus 50% (95% CI: 6-93) and 100% (95% CI: 69-100), respectively (P>0.05). The FDG-PET regarding the N and M status differed from the CT in 11 patients and led to modification of the planned management in 5 of them.
CONCLUSIONS: FDG-PET is more accurate than CT in defining N and M status. It can result in a reduction of unnecessary surgery in a significant number of patients. The combined PET-CT scan as a single imaging modality is expected to further improve diagnostic accuracy of FDG-PET.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631431     DOI: 10.1016/j.ijsu.2007.05.009

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  5 in total

1.  Oesophageal cancer: can imaging improve its assessment?

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

2.  Update: modern approaches to the treatment of localized esophageal cancer.

Authors:  James Welsh; Arya Amini; Anna Likhacheva; Jeremy Erasmus J; Daniel Gomez; Marta Davila; Reza J Mehran; Ritsuko Komaki; Zhongxing Liao; Wayne L Hofstetter; Jeffrey Lee H; Manoop S Bhutani; Jaffer A Ajani
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

3.  FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer.

Authors:  Keiichi Jingu; Rei Umezawa; Takaya Yamamoto; Kazuya Takeda; Yojiro Ishikawa; Noriyoshi Takahashi; Noriyuki Kadoya; Haruo Matsushita
Journal:  Int J Clin Oncol       Date:  2019-03-12       Impact factor: 3.402

4.  The early use of PET-CT alters the management of patients with esophageal cancer.

Authors:  R N Williams; S S Ubhi; C D Sutton; A L Thomas; J J Entwisle; D J Bowrey
Journal:  J Gastrointest Surg       Date:  2009-01-28       Impact factor: 3.452

5.  Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning? A comparison of image-based and pathological findings.

Authors:  Shinichi Shimizu; Masao Hosokawa; Kazuo Itoh; Masahiro Fujita; Hiroaki Takahashi; Hiroki Shirato
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.